6533-00-2
6533-00-2 结构式
基本信息
DL-甲基炔诺酮
炔诺孕酮
左炔诺孕酮
高诺酮
药典标准品
左炔孕酮
(+/-)-13-ETHYL-17ALPHA-HYDROXY-18,19-DINORPREGN-4-EN-20-YN-3-ONE
17-ALPHA-ETHYNYL-18-HOMO-19-NORTESTOSTERONE
18,19-DINOR-13-BETA-ETHYL-17-BETA-HYDROXY-4-PREGNEN-20-YN-3-ONE
18,19-DINOR-4-PREGNEN-20-YN-3-ONE
4-ESTREN-17-ALPHA-ETHYNYL-18-HOMO-17-BETA-OL-3-ONE(+/-)
4-GONEN-13BETA-ETHYL-17ALPHA-ETHYNYL-17BETA-OL-3-ONE
4-PREGNEN-13BETA-ETHYL-18,19-DINOR 17BETA-OL-3-ONE-20-YNE
d(-)-13beta-ethyl-17alpha-ethynyl-17beta-hydroxygon-4-en-3-one
dl-13b-ethyl-17a-ethynyl-17b-hydroxygon-4-en-3-one
D(-)-NORGESTREL
D-NORGESTREL
LEVONORGESTREL
NORGESTREL
NORGESTREL(LEVO)
NORPLANT
OVRETTE(R)
(+-)-13-ethyl-17-hydroxy-18,19-dinor-17-alpha-pregn-4-en-20-yn-3-one
13-ethyl-17-hydroxy-19-dinorpregn-4-en-20-yn-3-on(17-alpha)-(+-)-1
alpha-norgestrel
物理化学性质
安全数据
常见问题列表
Norgestrel (20 µM; 24 hours; 661W cells) treatment significantly increases cellular viability after serum deprivation and so it is demonstrated that Norgestrel is neuroprotective to stressed 661W cells.
Norgestrel (20 µM; 24 hours; 661W cells) treatment decreases apoptotic induced cleavage of PARP and caspase-3.
Norgestrel (20 µM; 6 hours; 661W cells) treatment bFGF is results in a significant upregulation of bFGF mRNA in photoreceptor cells.
Cell Viability Assay
| Cell Line: | 661W cells |
| Concentration: | 20 µM |
| Incubation Time: | 24 hours |
| Result: | Significantly increased cellular viability after serum deprivation. |
Western Blot Analysis
| Cell Line: | 661W cells |
| Concentration: | 20 µM |
| Incubation Time: | 24 hours |
| Result: | Decreased apoptotic induced cleavage of PARP and caspase-3. |
RT-PCR
| Cell Line: | 661W cells |
| Concentration: | 20 µM |
| Incubation Time: | 6 hours |
| Result: | A significant upregulation of bFGF mRNA over 1 hour. |
Norgestrel (100 mg/kg; intraperitoneal injection; for 6, 24 or 48 hours; Balb/c mice) treatment can prevent light-induced ROS in photoreceptor cells, and subsequent cell death. Norgestrel acts via post-translational modulation of the major antioxidant transcription factor Nrf2; bringing about its phosphorylation, subsequent nuclear translocation, and increases levels of its effector protein superoxide dismutase 2 (SOD 2 ).
| Animal Model: | Balb/c mice are born into and maintained in dim cyclic light |
| Dosage: | 100 mg/kg; |
| Administration: | Intraperitoneal injection; for 6, 24 or 48 hours |
| Result: | Increased expression and activation of Nrf2 via phosphorylation on serine 40, increased expression of its target antioxidant superoxide dismutase 2 (SOD 2 ), and reduced mitochondrial oxidative stress. |
2. 用作探亲避孕药：于探亲当晚开始服炔诺孕酮探亲避孕药，每天1片，服法同炔诺酮。
3. 用作事后避孕药：房事后72小时内口服2片复方炔诺孕酮事后避孕片，12小时后再服2片。
2. 少见的有头痛,胸、臀、腿特别是腓肠肌处疼痛,手臂和脚无力、麻木或疼痛,突然的或原因不明的呼吸短促，突然语言发音不清，突然视力改变、复视、不同程度失明等。
3. 长期应用可引起肝功能异常，缺血性心脏病发生率上升，妊娠早期时应用可能导致雄激素活性高引起的后代女婴男性化以及生殖道畸形(多见为尿道下裂)。
2. 维生素C能增强口服避孕药的作用，每天口服1g维生素C可使炔雌醇生物利用度从40%提高到60%～70%。
3. 与环孢素合用，可抑制环孢素的代谢清除，致其毒性增强，应避免合用。